— Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) reported a loss of $0.08 per share in the fourth quarter of 2019, in line with Wall Street expectation.
— Q4 revenue was flat at $1.2 million, vs. $920,000 expected.
— As at December 31, 2019, Titan had cash and cash equivalents of approximately $5.2 million.
— Launch of Sixmo may be delayed due to the impact of Covid-19.
— TTNP shares gained 4.4% during after-market trading hours.
Most Popular
NKE Earnings: Nike reports lower sales for Q3 2025
NIKE, Inc. (NYSE: NKE) has reported a decline in earnings for the third quarter of 2025, hurt by a slowdown in sales across all major markets and operating segments. The
NIO Infographic: A snapshot of Nio’s Q4 2024 earnings report
China-based electric car maker NIO Inc. (NYSE: NIO) on Friday reported a net loss for the fourth quarter of 2024. Revenues increased by double-digits during the three months. Total revenues
Infographic: How FedEx (FDX) performed in Q3 2025
FedEx Corp. (NYSE: FDX) reported revenue of $22.2 billion for the third quarter of 2025, up 2% compared to the same quarter a year ago. GAAP net income was $909
